KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Shares Outstanding (Weighted Average) (2016 - 2018)

BeOne Medicines (ONC) has disclosed Shares Outstanding (Weighted Average) for 10 consecutive years, with $109.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) fell 92.03% to $109.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $109.1 million, a 92.03% decrease, with the full-year FY2025 number at $109.1 million, down 92.03% from a year prior.
  • Shares Outstanding (Weighted Average) was $109.1 million for Q4 2025 at BeOne Medicines, down from $1.4 billion in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $1.4 billion in Q3 2025 to a low of $106.9 million in Q1 2025.
  • A 4-year average of $1.1 billion and a median of $1.4 billion in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Biggest YoY gain for Shares Outstanding (Weighted Average) was 92.03% in 2025; the steepest drop was 92.03% in 2025.
  • BeOne Medicines' Shares Outstanding (Weighted Average) stood at $1.3 billion in 2022, then grew by 1.98% to $1.4 billion in 2023, then increased by 0.59% to $1.4 billion in 2024, then plummeted by 92.03% to $109.1 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Shares Outstanding (Weighted Average) are $109.1 million (Q4 2025), $1.4 billion (Q3 2025), and $1.4 billion (Q2 2025).